+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are conducting a multicenter, randomized, double-blind, placebo-controlled study to evaluate the treatment of irritability associated with Autism Spectrum Disorder ASD in pediatric patients aged 5 to 17 years. The diagnosis of ASD is confirmed using established diagnostic criteria and interviews. The study aims to assess the safety and effectiveness of lumateperone in reducing irritability symptoms in this population. Participants are randomly assigned to one of three groups a high dose of lumateperone, a low dose of lumateperone, or a placebo. The study includes a screening period of up to 14 days to confirm eligibility, followed by a 6-week double-blind treatment period during which the study drug or placebo is taken once daily. After treatment, there is a 1-week safety follow-up visit to monitor any effects after stopping the study drug. During the study, participants will attend visits for assessments including symptom rating scales like the Aberrant Behavior Checklist for irritability and Clinical Global Impression-Severity. Safety will be monitored throughout the trial and during follow-up visits. The total participation time covers screening, treatment, and safety monitoring, with specific evaluations at baseline and week 6 to measure changes in irritability.

Age: 5Years - 17YearsAll GendersPhase 3
39 locations